Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 11, 2025
Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
GlobeNewswire
·
March 11, 2025
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the fourth …
Rate Insurance Launches “Grow for Good” Charity Referral Program to Support Communities Nationwide
GlobeNewswire
·
March 11, 2025
SCHAUMBURG, Ill., March 11, 2025 (GLOBE NEWSWIRE) -- Rate Insurance, LLC, a subsidiary of Rate and one of the fastest-growing national personal lines and small commercial insurance brokers, today announced the launch of its “Grow for Good” charity referral …
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution
GlobeNewswire
·
March 11, 2025
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand …
Little Leaves Behavioral Services Expands in Maryland and Virginia
GlobeNewswire
·
March 11, 2025
SILVER SPRING, Md., March 11, 2025 (GLOBE NEWSWIRE) -- Little Leaves Behavioral Services, a leading provider of center-based behavioral health services for preschool-aged children diagnosed with autism spectrum disorders (ASD), today announced plans to …
G-Flipons promise to improve the therapeutic efficacy of RNA editing
EIN Presswire
·
March 11, 2025
The paper resolves many unanswered questions about the recoding of RNAs by ADAR1 and the outcomes produced in a cell CHARLESTOWN, MA, UNITED STATES, March 11, 2025 /EINPresswire.com/ -- The double-stranded RNA editing enzyme ADAR1 offers excellent …
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
GlobeNewswire
·
March 11, 2025
On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its …
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule
GlobeNewswire
·
March 11, 2025
LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and …
Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline
GlobeNewswire
·
March 11, 2025
• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities. WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- …
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
GlobeNewswire
·
March 11, 2025
LONDON, March 11, 2025 (GLOBE NEWSWIRE) -- Kaerus Bioscience (www.kaerusbio.com), a clinical-stage biopharmaceutical company created by Medicxi for the development of therapeutics for rare genetic syndromes of neurodevelopment, today announces the …
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
GlobeNewswire
·
March 11, 2025
Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s disease This encouraging clinical trial data adds to the body of evidence supporting the safety of …
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th
GlobeNewswire
·
March 11, 2025
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will …
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
GlobeNewswire
·
March 11, 2025
DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while …
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel
GlobeNewswire
·
March 11, 2025
WINNIPEG, Manitoba, March 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech”) announces that it has concluded a three-year distribution agreement with Best Buy Medical Canada for its revyve™ Antimicrobial Wound Gel …
Prenetics to Participate in the 37th Annual ROTH Conference
GlobeNewswire
·
March 11, 2025
CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday …
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
GlobeNewswire
·
March 11, 2025
SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its strategic decision …
Cellectar Biosciences to Present at the 37th Annual Roth Conference
GlobeNewswire
·
March 11, 2025
FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today …
Teladoc Health Expands Connected Care Partnerships
GlobeNewswire
·
March 11, 2025
PURCHASE, NY, March 11, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the expansion of its connected care partnerships across new care categories including digestive health, centers of excellence, …
genXtraits and Norfolk Healthy Produce to collaborate on breeding of nutritionally enhanced tomatoes
GlobeNewswire
·
March 11, 2025
ALAMEDA ISLAND, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- genXtraits Inc. (genXtraits) and Norfolk Healthy Produce Inc. (NHP) today announced that they have entered into an agreement under which the companies will collaborate to breed nutritionally …
Better Life Partners Expands into North Carolina with Whole-Person Care for Substance Use Disorders
GlobeNewswire
·
March 11, 2025
WATERTOWN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Better Life Partners is expanding its mission of compassionate, community-based care to North Carolina, and now offers virtual and in-person treatment for opioid and alcohol use disorders. With a …
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
GlobeNewswire
·
March 11, 2025
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full …